Table 3.
Results from the EORTC QLQ, ophthalmologic module (OPT), evaluated over time in different adjuvant treatment groups
| EORTC QLQ-C30 | Type of adjuvant treatment |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| no adjuvant treatment (OS) |
intravitreal injection (IN) |
endoresection/drainage (SU) |
||||||||||
| mean | ±SD | t1:t2 | t2:t3 | mean | ±SD | t1:t2 | t2:t3 | mean | ±SD | t1:t2 | t2:t3 | |
| Functional scales time | ||||||||||||
| Ocular irritation* | ||||||||||||
| t1 | 26.59 | 20.81 | p < 0.001 | 24.05 | 20.43 | p = 0.807 | 28.72 | 16.89 | p = 0.389 | |||
| t2 | 19.34 | 17.75 | p < 0.003 | 21.18 | 20.31 | p = 0.432 | 30.37 | 19.17 | p = 0.201 | |||
| t3 | 24.11 | 21.25 | 20.32 | 19.38 | 26.62 | 13.90 | ||||||
| Visual impairment | ||||||||||||
| t1 | 16.27 | 22.32 | p = 0.741 | 28.76 | 29.15 | p = 0.788 | 25.10 | 25.71 | p = 0.053 | |||
| t2 | 16.67 | 20.71 | p = 0.701 | 24.31 | 16.34 | p = 0.075 | 34.44 | 26.96 | p = 0.079 | |||
| t3 | 17.58 | 23.20 | 35.04 | 23.94 | 29.71 | 22.45 | ||||||
| Worry about recurrence | ||||||||||||
| t1 | 40.77 | 29.72 | p = 0.885 | 61.76 | 30.05 | p = 0.629 | 50.93 | 30.69 | p = 0.585 | |||
| t2 | 40.35 | 28.01 | p = 0.843 | 55.56 | 28.60 | p = 0.506 | 53.06 | 27.81 | p = 0.867 | |||
| t3 | 38.39 | 27.19 | 51.79 | 30.52 | 50.35 | 22.98 | ||||||
| Problems with exterior aspect* | ||||||||||||
| t1 | 29.41 | 28.40 | p = 0.091 | 29.41 | 30.35 | p = 0.246 | 17.28 | 23.33 | p = 0.041 | |||
| t2 | 21.11 | 25.83 | p = 0.121 | 16.67 | 23.57 | p = 0.528 | 26.11 | 27.57 | p = 0.411 | |||
| t3 | 25.60 | 25.42 | 11.90 | 17.82 | 20.83 | 27.47 | ||||||
| Functional problems visual impairment* | ||||||||||||
| t1 | 19.39 | 22.51 | p = 0.481 | 31.05 | 28.94 | p = 0.932 | 24.31 | 22.66 | p = 0.002 | |||
| t2 | 19.76 | 20.60 | p = 0.006 | 29.90 | 19.13 | p = 0.272 | 36.48 | 24.49 | p = 0.009 | |||
| t3 | 22.54 | 21.58 | 26.19 | 20.26 | 29.40 | 22.07 | ||||||
| Functional problems with treated eye** | ||||||||||||
| t1 | 27.67 | 23.08 | p = 1.000 | 39.22 | 24.48 | p = 0.615 | 31.55 | 20.82 | p = 0.005 | |||
| t2 | 27.93 | 19.72 | p = 0.241 | 34.90 | 19.65 | p = 0.263 | 42.41 | 25.49 | p = 0.429 | |||
| t3 | 31.24 | 32.10 | 39.40 | 26.92 | 37.22 | 22.75 | ||||||
| Problems with driving* | ||||||||||||
| t1 | 27.33 | 30.45 | p = 0.473 | 34.44 | 27.07 | p = 0.454 | 21.79 | 27.39 | p < 0.001 | |||
| t2 | 28.95 | 27.19 | p = 0.063 | 28.13 | 21.70 | p = 0.345 | 53.45 | 34.90 | p = 0.009 | |||
| t3 | 32.08 | 29.02 | 30.95 | 26.03 | 35.51 | 29.43 | ||||||
| Single items | ||||||||||||
| Headache* | ||||||||||||
| t1 | 16.07 | 24.61 | p = 0.374 | 21.57 | 33.21 | p = 0.114 | 16.05 | 28.30 | p = 0.037 | |||
| t2 | 18.03 | 29.55 | p = 0.818 | 10.42 | 15.96 | p = 0.336 | 31.03 | 32.04 | p = 0.012 | |||
| t3 | 18.45 | 26.91 | 11.90 | 16.57 | 15.28 | 25.97 | ||||||
| Problems with reading | ||||||||||||
| t1 | 36.31 | 29.32 | p = 0.148 | 56.86 | 30.65 | p =1.000 | 35.71 | 23.88 | p = 0.148 | |||
| t2 | 39.89 | 30.32 | p = 0.897 | 56.86 | 25.72 | p = 0.213 | 40.23 | 27.28 | p = 0.891 | |||
| t3 | 41.67 | 34.38 | 61.90 | 22.81 | 43.06 | 25.02 | ||||||
Values are the mean scores and standard deviations (SD). t1, immediately after PT; t2,3 months after PT; t3,12 months after PT. Bold font indicates a significant change between the indicated assessment points (p value ≤ 0.05), according to the paired Wilcoxon signed-rank test. QLQ, quality of life questionnaire; EORTC, European Organization for Research and Treatment of Cancer; PT, proton therapy. * p ≤ 0.05 and ** p ≤ 0.1 indicate a significant interaction between the treatment type and time, according to a mixed generalized linear model.